Guest Editors:
Priscilla Brastianos, MD, Harvard Medical School, United States
Associate Professor Alexandra Zimmer, MD, MSc, Oregon Health & Science University, United States
Acta Neuropathologica Communications is calling for submissions to our new Collection "Investigating the Biology of Brain Metastases".
Image credit: Naeblys/Getty Images/iStock
Leptomeningeal disease (LMD) is a devastating manifestation of late-stage cancer which currently suffers from a lack of effective therapeutics. Unfortunately, a significant obstacle preventing the widespread d...
Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous s...
KRAS mutations are prevalent in brain metastases (BM) from non-small cell lung cancer (NSCLC). The activity of KRAS-G12C selective, brain-penetrant small molecule inhibitor adagrasib was recently demonstrated ...
Breast cancer is one of the leading causes of death worldwide. The aggressive behaviour of breast tumor results from their metastasis. Notably, the brain tissue is one of the common regions of metastasis, ther...
Melanoma brain metastases (MBMs) are diagnosed in up to 60% of metastatic melanoma patients. Previous studies have identified clinical factors that correlate with overall survival (OS) after MBM diagnosis. How...
Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) have increasingly been reported to impact the brain metastatic process of solid tumors. However, data on intra-individual differenc...
The incidence of brain metastases (BrM) in patients with metastatic melanoma is reported to be 30–50% and constitutes the third most frequent BrM after breast and renal cancers. Treatment strategies including ...
Melanoma is the most serious type of skin cancer that frequently spreads to other organs of the human body. Especially melanoma metastases to the brain (intracranial metastases) are hard to treat and a major c...
Brain metastases occur in 1% of sarcoma cases and are associated with a median overall survival of 6 months. We report a rare case of a brain metastasis with unique radiologic and histopathologic features in a...
Inflammasomes, primarily responsible for the activation of IL-1β, have emerged as critical regulators of the tumor microenvironment. By using in vivo and in vitro brain metastasis models, as well as human samp...
This Collection is seeking articles that focus on the biology of brain metastases, with an emphasis on the molecular characteristics of brain metastases, biomarkers that indicate response and resistance to different therapies, the development of preclinical models, and an examination of the unique tumor immune microenvironment of the brain. We also welcome articles that explore new and innovative therapeutic targets or treatment methods, particularly in preclinical models of brain metastases. Additionally, we are interested in studies that examine human tissue samples from patients with brain metastases, taken especially before and after therapy.
Overall, this Collection aims to bring together the latest research on brain metastases biology to inform the scientific community and ultimately lead to improved treatment options for patients.
Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via SNAPP. During the submission process you will be asked whether you are submitting to a Collection, please select "Investigating the Biology of Brain Metastases" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.